@lungenforschung.bsky.social
Zur Anmeldung: us02web.zoom.us/webinar/regi...
Welcome! You are invited to join a webinar: ASCO Highlights Lung Cancer 2025. After registering, you will receive a confirmation email about joining the webinar.
Welcome! You are invited to join a webinar: ASCO Highlights Lung Cancer 2025. After registering, you will receive a confirmation email about joining the webinar.
us02web.zoom.us
May 8, 2025 at 1:17 PM
Zur Anmeldung: us02web.zoom.us/webinar/regi...
Link zur Studie: pubmed.ncbi.nlm.nih.gov/40295241/
Multidisciplinary treatment of advanced or metastatic ALK-positive non-small cell lung cancer: Real-world data on Brigatinib combined with local therapy - PubMed
Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) often shows incomplete responses and progression despite tyrosine kinase inhibitor (TKI) therapy. Preliminary data suggest ...
pubmed.ncbi.nlm.nih.gov
May 5, 2025 at 9:43 AM
Link zur Studie: pubmed.ncbi.nlm.nih.gov/40295241/
Zur Anmeldung: www.ontargetlungcancer.com
April 25, 2025 at 3:11 PM
Zur Anmeldung: www.ontargetlungcancer.com
Zu den ePosters: 1. cslide.ctimeetingtech.com/coasis_21204..., 2. cslide.ctimeetingtech.com/coasis_21204...
cslide.ctimeetingtech.com
April 4, 2025 at 12:04 PM
Zu den ePosters: 1. cslide.ctimeetingtech.com/coasis_21204..., 2. cslide.ctimeetingtech.com/coasis_21204...
Mehr erfahren: doi.org/10.1200/JCO-...
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
PURPOSEMobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets EGFR exon 20 insertion (ex20ins) mutations in non–small cell lung cancer (NSCLC). This open-label, phase III trial (EXCLAIM-2: ClinicalTrials.gov ...
doi.org
February 25, 2025 at 12:09 PM
Mehr erfahren: doi.org/10.1200/JCO-...
Redirecting
doi.org
February 7, 2025 at 2:48 PM
